Cintas (CTAS)
(Delayed Data from NSDQ)
$205.62 USD
-0.19 (-0.09%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $205.53 -0.09 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$205.62 USD
-0.19 (-0.09%)
Updated Nov 1, 2024 03:59 PM ET
After-Market: $205.53 -0.09 (-0.04%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Zacks News
Zacks Market Edge Highlights: NVIDIA, e.l.f. Beauty, Walt Disney, Walgreens Boots Alliance and Cintas
by Zacks Equity Research
NVIDIA, e.l.f. Beauty, Walt Disney, Walgreens Boots Alliance and Cintas are part of the Zacks Market Edge blog.
How to Use the 50 and 200-Day Moving Averages
by Tracey Ryniec
New to technical chart analysis? David Bartosiak explains the basics.
Stock Market News for Sep 27, 2023
by Zacks Equity Research
U.S. stock markets fell sharply lower on Tuesday following the release of several weak economic data.
Cintas (CTAS) Q1 Earnings & Revenues Top Estimates, Increase Y/Y
by Zacks Equity Research
Cintas' (CTAS) Q1 results benefit from higher revenues across all segments. The bottom line increases on a year-over-year basis despite higher costs.
Cintas (CTAS) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Cintas (CTAS) give a sense of how the business performed in the quarter ended August 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Cintas (CTAS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Cintas (CTAS) delivered earnings and revenue surprises of 1.37% and 0.75%, respectively, for the quarter ended August 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include Constellation Brands, Owens Corning, Belden, Cintas and National Fuel Gas
by Zacks Equity Research
Constellation Brands, Owens Corning, Belden, Cintas and National Fuel Gas are part of the Zacks Screen of the Week article.
Buy 5 Stocks With Upgraded Broker Ratings for Solid Profits
by Swayta Shah
As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We pick Constellation Brands (STZ), Owens Corning (OC), Belden (BDC), Cintas (CTAS) and National Fuel Gas (NFG) as these witness rating upgrades.
CalMaine Foods (CALM) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
CalMaine Foods' (CALM) first-quarter 2024 results are likely to reflect the recent downtrend in average selling prices for conventional eggs as well as low sales volumes.
Cintas (CTAS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Cintas (CTAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cintas (CTAS) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Cintas (CTAS) is expected to put up a strong show in Q1 on the back of strength across its health and wellness businesses, focus on operational executions and pricing actions.
Cintas (CTAS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Cintas (CTAS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Cintas Corporation (CTAS) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Cintas (CTAS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
If You Invested $1000 in Cintas a Decade Ago, This is How Much It'd Be Worth Now
by Zacks Equity Research
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Research Solutions Inc. (RSSS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Research Solutions Inc. (RSSS) delivered earnings and revenue surprises of 200% and 2.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Cintas (CTAS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Cintas (CTAS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cintas (CTAS) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Cintas (CTAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Want Better Returns? Don?t Ignore These 2 Industrial Products Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group
by Zacks Equity Research
Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group are part of the Zacks top Analyst Blog.
Top Analyst Reports for Humana, Cintas & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Humana Inc. (HUM), Cintas Corporation (CTAS) and Biogen Inc. (BIIB).
Why Cintas (CTAS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why You Should Hold on to Cintas (CTAS) Stock Now
by Zacks Equity Research
Cintas (CTAS) is set to benefit from robust health and wellness businesses, increased productivity level and new product launches. The company's measures to reward its shareholders are encouraging.
3 Stocks to Buy Amid the August Market Pullback and Hold
by Benjamin Rains
Let's dig into three stocks that investors might want to buy now during the August pullback and hold for the long haul.